Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Lutje Hulsik, David"'
Autor:
Dang, Xibei, Guelen, Lars, Lutje Hulsik, David, Ermakov, Grigori, Hsieh, Edward J., Kreijtz, Joost, Stammen-Vogelzangs, Judith, Lodewijks, Imke, Bertens, Astrid, Bramer, Arne, Guadagnoli, Marco, Nazabal, Alexis, van Elsas, Andrea, Fischmann, Thierry, Juan, Veronica, Beebe, Amy, Beaumont, Maribel, van Eenennaam, Hans
Publikováno v:
mAbs; Jan-Dec2023, Vol. 15 Issue 1, p1-12, 12p
Autor:
Hans van Eenennaam, Driessen Lilian, Jan Paul Medema, Kenneth C. Anderson, Astrid Bertens, Andrea van Elsas, John Dulos, Lutje Hulsik David, Marc Snippert, Kate Cameron, Tai Yu-Tzu, Marco Guadagnoli
Publikováno v:
Blood. 128:2112-2112
A PRoliferation Inducing Ligand (APRIL, TNFSF13), is a ligand for the receptors BCMA and TACI. APRIL serum levels are enhanced in patients diagnosed with Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), and Colorectal Carcinoma correlated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ce4a9dcf30a714e81c3f61f6871c4ea
https://doi.org/10.1182/blood.v128.22.2112.2112
https://doi.org/10.1182/blood.v128.22.2112.2112
Autor:
Voets, Erik, Paradé, Marc, Lutje Hulsik, David, Spijkers, Sanne, Janssen, Wout, Rens, Joost, Reinieren-Beeren, Inge, van den Tillaart, Gilbert, van Duijnhoven, Sander, Driessen, Lilian, Habraken, Maurice, van Zandvoort, Peter, Kreijtz, Joost, Vink, Paul, van Elsas, Andrea, van Eenennaam, Hans
Publikováno v:
Journal for ImmunoTherapy of Cancer; 12/4/2019, Vol. 7 Issue 1, pN.PAG-N.PAG, 1p
Autor:
King LA; Department of Medical Oncology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands., de Jong M; Department of Medical Oncology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands., Veth M; Department of Medical Oncology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands., Lutje Hulsik D; Lava Therapeutics NV, Utrecht, Netherlands., Yousefi P; Lava Therapeutics NV, Utrecht, Netherlands., Iglesias-Guimarais V; Lava Therapeutics NV, Utrecht, Netherlands., van Helden PM; Lava Therapeutics NV, Utrecht, Netherlands., de Gruijl TD; Department of Medical Oncology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Amsterdam, Netherlands.; Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands., van der Vliet HJ; Department of Medical Oncology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Amsterdam, Netherlands.; Lava Therapeutics NV, Utrecht, Netherlands.
Publikováno v:
Frontiers in oncology [Front Oncol] 2024 Oct 18; Vol. 14, pp. 1474007. Date of Electronic Publication: 2024 Oct 18 (Print Publication: 2024).
Autor:
Lameris R; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands., Shahine A; Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia., Veth M; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands., Westerman B; Department of Neurosurgery, Cancer Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands., Godfrey DI; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia., Lutje Hulsik D; LAVA Therapeutics, Utrecht, The Netherlands., Brouwer P; LAVA Therapeutics, Utrecht, The Netherlands., Rossjohn J; Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.; Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK., de Gruijl TD; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands., van der Vliet HJ; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands jj.vandervliet@amsterdamumc.nl.; LAVA Therapeutics, Utrecht, The Netherlands.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Dec 01; Vol. 11 (12). Date of Electronic Publication: 2023 Dec 01.
Autor:
Guelen L; BioNovion/Aduro Biotech Europe, Oss, The Netherlands., Fischmann TO; Discovery, Preclinical and Translational Medicine, Merck & Co Inc, Kenilworth, New Jersey, USA., Wong J; Discovery, Preclinical and Translational Medicine, Merck & Co Inc, South San Francisco, California, USA., Mauze S; Discovery, Preclinical and Translational Medicine, Merck & Co Inc, South San Francisco, California, USA., Guadagnoli M; BioNovion/Aduro Biotech Europe, Oss, The Netherlands., Bąbała N; Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Wagenaars J; BioNovion/Aduro Biotech Europe, Oss, The Netherlands., Juan V; Discovery, Preclinical and Translational Medicine, Merck & Co Inc, South San Francisco, California, USA., Rosen D; Discovery, Preclinical and Translational Medicine, Merck & Co Inc, South San Francisco, California, USA., Prosise W; Discovery, Preclinical and Translational Medicine, Merck & Co Inc, Kenilworth, New Jersey, USA., Habraken M; BioNovion/Aduro Biotech Europe, Oss, The Netherlands., Lodewijks I; BioNovion/Aduro Biotech Europe, Oss, The Netherlands., Gu D; Discovery, Preclinical and Translational Medicine, Merck & Co Inc, South San Francisco, California, USA., Stammen-Vogelzangs J; BioNovion/Aduro Biotech Europe, Oss, The Netherlands., Yu Y; Discovery, Preclinical and Translational Medicine, Merck & Co Inc, South San Francisco, California, USA., Baker J; Discovery, Preclinical and Translational Medicine, Merck & Co Inc, South San Francisco, California, USA., Lutje Hulsik D; BioNovion/Aduro Biotech Europe, Oss, The Netherlands., Driessen-Engels L; BioNovion/Aduro Biotech Europe, Oss, The Netherlands., Malashock D; Discovery, Preclinical and Translational Medicine, Merck & Co Inc, South San Francisco, California, USA., Kreijtz J; BioNovion/Aduro Biotech Europe, Oss, The Netherlands., Bertens A; BioNovion/Aduro Biotech Europe, Oss, The Netherlands., de Vries E; Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Bovens A; Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Bramer A; BioNovion/Aduro Biotech Europe, Oss, The Netherlands., Zhang Y; Clinical Development, Merck & Co Inc, Rahway, New Jersey, USA., Wnek R; Discovery, Preclinical and Translational Medicine, Merck & Co Inc, Kenilworth, New Jersey, USA., Troth S; Discovery, Preclinical and Translational Medicine, Merck & Co Inc, West Point, Pennsylvania, USA., Chartash E; Clinical Development, Merck & Co Inc, Rahway, New Jersey, USA., Dobrenkov K; Clinical Development, Merck & Co Inc, Rahway, New Jersey, USA., Sadekova S; Discovery, Preclinical and Translational Medicine, Merck & Co Inc, South San Francisco, California, USA., van Elsas A; BioNovion/Aduro Biotech Europe, Oss, The Netherlands., Cheung JK; Process Research and Development, Merck & Co Inc, Kenilworth, New Jersey, USA., Fayadat-Dilman L; Discovery, Preclinical and Translational Medicine, Merck & Co Inc, South San Francisco, California, USA., Borst J; Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Beebe AM; Discovery, Preclinical and Translational Medicine, Merck & Co Inc, South San Francisco, California, USA amy.beebe@merck.com., Van Eenennaam H; BioNovion/Aduro Biotech Europe, Oss, The Netherlands.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Sep; Vol. 10 (9).
Autor:
Lutje Hulsik D; Unit of Virus Host Cell Interactions (UVHCI), UMI 3265, Université Joseph Fourier-EMBL-CNRS, Grenoble, France., Liu YY, Strokappe NM, Battella S, El Khattabi M, McCoy LE, Sabin C, Hinz A, Hock M, Macheboeuf P, Bonvin AM, Langedijk JP, Davis D, Forsman Quigley A, Aasa-Chapman MM, Seaman MS, Ramos A, Poignard P, Favier A, Simorre JP, Weiss RA, Verrips CT, Weissenhorn W, Rutten L
Publikováno v:
PLoS pathogens [PLoS Pathog] 2013 Mar; Vol. 9 (3), pp. e1003202. Date of Electronic Publication: 2013 Mar 07.
Autor:
Sabin C; Unit of Virus Host Cell Interactions, UMI 3265, Université Joseph Fourier-EMBL-CNRS, Grenoble, France., Corti D, Buzon V, Seaman MS, Lutje Hulsik D, Hinz A, Vanzetta F, Agatic G, Silacci C, Mainetti L, Scarlatti G, Sallusto F, Weiss R, Lanzavecchia A, Weissenhorn W
Publikováno v:
PLoS pathogens [PLoS Pathog] 2010 Nov 18; Vol. 6 (11), pp. e1001195. Date of Electronic Publication: 2010 Nov 18.
Autor:
de Morrée A; Center for Human Genetics, Leiden University Medical Center, Leiden, The Netherlands., Lutje Hulsik D, Impagliazzo A, van Haagen HH, de Galan P, van Remoortere A, 't Hoen PA, van Ommen GB, Frants RR, van der Maarel SM
Publikováno v:
PloS one [PLoS One] 2010 Aug 04; Vol. 5 (8), pp. e11940. Date of Electronic Publication: 2010 Aug 04.
Autor:
Hinz A; Unit of Virus Host Cell Interactions (UVHCI), UMI 3265, Université Joseph Fourier-EMBL-CNRS, Grenoble, France., Lutje Hulsik D, Forsman A, Koh WW, Belrhali H, Gorlani A, de Haard H, Weiss RA, Verrips T, Weissenhorn W
Publikováno v:
PloS one [PLoS One] 2010 May 05; Vol. 5 (5), pp. e10482. Date of Electronic Publication: 2010 May 05.